Duodenal Variceal Rupture During Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma.

Mio Tsuruoka,Jun Inoue,Keishi Ouchi,Kaname Uno,Hideaki Itami,Masashi Ninomiya,Tomoaki Iwata,Akitoshi Sano,Kosuke Sato,Masazumi Onuki,Satoko Sawahashi,Tomoyuki Koike,Atsushi Masamune

DOI: https://doi.org/10.2169/internalmedicine.0629-22

2022-01-01

Internal Medicine

Abstract:Duodenal varices are detected infrequently, and their rupture is very rare. We encountered an 87-year-old man who developed duodenal varices rupture during chemotherapy with atezolizumab and bevacizumab (ATZ/BV) for hepatocellular carcinoma. We identified massive bleeding of a ruptured varix in the horizontal portion of the duodenum with emergency esophagogastroduodenoscopy (EGD). Successful hemostasis was achieved by endoscopic injection sclerotherapy with Histoacryl. Although ATZ/BV can cause esophageal varices rupture, there have been no cases of duodenal varices rupture. We should take care to check the duodenal varices as well as esophagogastric varices before ATZ/BV treatment.